Drug
Allo 647
Allo 647: highest development phase Phase 2, developed by Allogene Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Allogene Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALLO-647 NCT05714345 | Phase 2 | Relapsed/Refractory Large B Cell Lymphoma |
Latest
No recent events.
Follow Allo 647 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.